April 19, 2022 PAO-04-22-R250-66
At another stop on the Road to 50 States, Jonathan Rigby, President, and Group CEO at Revolo Biotherapeutics, talks to Nigel about the company's mission and vision and where Revolo is stepping in to address shortcomings in therapies for autoimmune and allergic diseases.
Jonathan Rigby is an experienced CEO with three decades of experience creating value and opportunities for companies in the pharmaceutical, biotech, and drug-delivery technology industries. He currently serves as the CEO of Revolo Biotherapeutics, a biotechnology company setting out to revolutionize the treatment for autoimmune and allergic diseases through the development of therapies that reset the immune system to achieve superior long-term disease remission. He holds a Bachelor of Science Degree with Honors in biological sciences from Sheffield University, U.K., and an MBA from Portsmouth University, U.K.